The Swiss biotech company Swiss Rockets AG is launching a new business model to meet the challenges in the field of cancer research. Swiss Rockets invests in the most promising technologies, and actively drives them forward.
The Swiss Rockets business model will bring advantages first and foremost to cancer patients, but also to researchers of new active substances, and investors. Forward-looking treatment methods within the therapeutic area of oncology will be identified, supported, and commercialized through the combining of services into an incubator for new oncology projects, through targeted investments along the entire development process of new drugs, through the deployment of Swiss Rockets experts and through the company’s own global distribution network.
Swiss Rockets’ approach differs from traditional venture capital investors in that the company cooperates closely with universities, research institutions, and acclaimed experts. An integrated ecosystem will support researchers in their work on new anti-cancer substances. The working processes associated with the collection and analysis of tissue samples will be significantly improved, with the objective of making personalized diagnosis more affordable. Swiss Rockets will mobilize extensive financial resources to develop groundbreaking therapies, while researchers will participate in the success of newly created blockbuster medicines.
Mr. Veselin Jevrosimovic, Chairman of the Board of Directors of Swiss Rockets AG, explains: “From my own experience, I know how important it is to create an environment that fosters cooperation between entrepreneurs and experts to develop a successful company. Swiss Rockets has the right team to provide solutions in the therapeutic areas of cancer, with the speed and power of rockets.”
Dr. Vladimir Cmiljanovic, Chief Executive Officer of Swiss Rockets AG, adds: “Our ambition is to break new ground in the treatment of cancers. This includes the development of new active ingredients and improved diagnostics. Our practical experience in cancer research puts us in an ideal position to provide the best possible working conditions for the experts working on our projects.”
Swiss Rockets is developing several innovative active ingredients and medical devices with the potential to significantly improve the well-being of patients. These include vaccines against breast cancer, immunotherapies against leukemia, active substances against HPV infections and cervical cancer, and new biopsy devices. Most of these projects are in preclinical development, while the biopsy device is already available on the market. In order to establish a balanced range of technologies and services and to be able to support the projects financially during the development phase, Swiss Rockets AG has started to raise capital through an equity financing round.
About Swiss Rockets AG:
Swiss Rockets AG, Basel, founded in 2018, is implementing a paradigm shift in healthcare. Cancer patients will benefit from new treatment therapies developed using innovative and disruptive methods. The Swiss-Rockets team combines the necessary specialist knowledge and experience to efficiently and sustainably break new ground in cancer medicine.
The Board of Directors of Swiss Rockets AG is chaired by Veselin Jevrosimovic, a successful entrepreneur and the founder of Comtrade, one of the largest IT companies in south-eastern Europe. Other board members are Prof. Dr. Michael N. Hall, a renowned researcher, and Professor at the Biozentrum of the University of Basel, and André Debrunner, a financial expert and fund manager at Northern Trust Corporation.
The founder and CEO of Swiss Rockets is Dr. Vladimir Cmiljanovic, a medicinal chemist with more than 15 years’ experience in the development of cancer drugs. Together with his sister Dr. Natasa Cmiljanovic, co-founder and Chief Scientific Officer of Swiss Rockets, he developed oncology drugs at the University of Basel and subsequently founded and successfully led several biotech companies. Manuel Ebner, Strategic Advisor of Swiss Rockets and CEO for Switzerland at the Bank of America Merrill Lynch, and Dr. Thomas Sander, Scientific Advisor of Swiss Rockets and one of the first employees of the biotech company Actelion, are also co-founders of Swiss Rockets AG.